RPV LA

DRUG4 trials

Sponsors

ViiV Healthcare, Janssen Research & Development, LLC

Conditions

HIV InfectionsHealthy

Phase 1

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

CompletedNCT05112939

Janssen Research & Development, LLCHealthy

Start: 2021-11-16End: 2024-05-23Updated: 2026-05-12

Phase 2

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

CompletedNCT03639311

ViiV HealthcareHIV Infections

Start: 2018-09-24End: 2023-01-30Updated: 2024-06-11

Phase 3

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

CompletedNCT04399551

ViiV HealthcareHIV Infections

Start: 2020-09-28End: 2023-03-13Updated: 2024-04-05

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

Not yet recruitingNCT07650916

ViiV HealthcareHIV Infections

Start: 2026-06-29End: 2029-09-04Target: 564Updated: 2026-06-23

Related Papers

Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.

2025-07-041 citations

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)—a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol

BMJ Open2025-04-012 citations

Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations

Journal of the International AIDS Society2024-07-017 citations

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

AIDS2021-10-1334 citations

2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results

Open Forum Infectious Diseases2019-10-018 citations